State of Alaska Department of Revenue increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 15,607 shares of the medical instruments supplier’s stock after purchasing an additional 400 shares during the period. State of Alaska Department of Revenue’s holdings in LeMaitre Vascular were worth $507,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Conestoga Capital Advisors LLC grew its stake in LeMaitre Vascular by 4.8% in the second quarter. Conestoga Capital Advisors LLC now owns 1,802,869 shares of the medical instruments supplier’s stock worth $47,596,000 after purchasing an additional 81,788 shares during the period. State Street Corp grew its stake in LeMaitre Vascular by 2.2% in the first quarter. State Street Corp now owns 670,603 shares of the medical instruments supplier’s stock worth $16,711,000 after purchasing an additional 14,244 shares during the period. Copeland Capital Management LLC grew its stake in LeMaitre Vascular by 6.4% in the second quarter. Copeland Capital Management LLC now owns 641,351 shares of the medical instruments supplier’s stock worth $16,932,000 after purchasing an additional 38,406 shares during the period. Geode Capital Management LLC grew its stake in LeMaitre Vascular by 5.6% in the first quarter. Geode Capital Management LLC now owns 272,185 shares of the medical instruments supplier’s stock worth $6,782,000 after purchasing an additional 14,468 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in LeMaitre Vascular by 2.3% in the second quarter. Bank of New York Mellon Corp now owns 237,281 shares of the medical instruments supplier’s stock worth $6,264,000 after purchasing an additional 5,369 shares during the period. 83.61% of the stock is currently owned by institutional investors.

In other news, Director David B. Roberts bought 7,074 shares of the stock in a transaction on Friday, August 14th. The shares were bought at an average price of $28.35 per share, with a total value of $200,547.90. Following the completion of the acquisition, the director now owns 43,557 shares in the company, valued at $1,234,840.95. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Trent G. Kamke sold 13,804 shares of the stock in a transaction dated Friday, July 24th. The shares were sold at an average price of $33.00, for a total value of $455,532.00. Following the completion of the transaction, the insider now directly owns 21,558 shares in the company, valued at approximately $711,414. The disclosure for this sale can be found here. Insiders have sold 20,588 shares of company stock worth $684,053 over the last ninety days. 16.50% of the stock is currently owned by insiders.

LeMaitre Vascular stock opened at $32.31 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.07 and a quick ratio of 1.03. LeMaitre Vascular, Inc. has a one year low of $18.76 and a one year high of $38.64. The stock has a market capitalization of $653.53 million, a PE ratio of 39.89, a price-to-earnings-growth ratio of 4.35 and a beta of 1.33. The business’s fifty day moving average is $32.23 and its 200 day moving average is $28.20.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $0.17 EPS for the quarter, beating the consensus estimate of $0.01 by $0.16. LeMaitre Vascular had a return on equity of 11.13% and a net margin of 14.36%. The company had revenue of $24.85 million for the quarter, compared to analysts’ expectations of $15.58 million. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 0.77 EPS for the current fiscal year.

A number of equities research analysts have recently commented on LMAT shares. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Canaccord Genuity increased their target price on LeMaitre Vascular from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Lake Street Capital increased their target price on LeMaitre Vascular from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. TheStreet raised LeMaitre Vascular from a “c” rating to a “b-” rating in a research note on Thursday, August 13th. Finally, Stifel Nicolaus increased their target price on LeMaitre Vascular from $25.00 to $30.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $33.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Recommended Story: Why do commodities matter?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.